Suppr超能文献

术前免疫抑制是否会影响克罗恩病患者手术后的非计划性住院再入院?

Does preoperative immunosuppression influence unplanned hospital readmission after surgery in patients with Crohn's disease?

机构信息

Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.

出版信息

Dis Colon Rectum. 2012 May;55(5):563-8. doi: 10.1097/DCR.0b013e3182468961.

Abstract

BACKGROUND

Steroids, immunomodulators, and biologics, often in combination with one another, are frequently used in the treatment of Crohn's disease. Retrospective studies have yielded conflicting results regarding the influence of preoperative immunosuppressive therapy on postoperative complications after surgery in Crohn's disease. Unplanned hospital readmission is considered to be an index of quality surgical care.

OBJECTIVE

The aim of this study was to examine the association, if any, between the number of preoperative immunosuppressive therapies and unplanned hospital readmission after surgery in patients with Crohn's disease.

DESIGN

Consecutive patients with Crohn's disease requiring abdominal surgery were identified from a prospectively maintained database. Preoperative immunosuppressive therapy within 3 months before surgery was categorized into 3 classes: steroids, immunomodulators, and biologics.

MAIN OUTCOME MEASURES

Unplanned readmission occurring within 30 days of hospital discharge was assessed. Trend analysis was performed with the use of the Cochrane-Armitage test.

RESULTS

The study group included 338 patients. Preoperative medical therapy included steroids (n = 199; 59%), immunomodulators (n = 162; 48%), and biologics (n = 59; 18%). Sixty-three patients (19%) were not treated with any immunosuppressive medications preoperatively, whereas 148 patients (44%), 108 patients (32%), and 19 patients (6%) were treated with 1, 2, or 3 classes of immunosuppressive medications. Twenty-eight patients (8.3%) had an unplanned readmission. The incidence of unplanned readmission was similar among patients treated with steroids (11%), immunomodulators (9%), and biologics (12%). The incidence of unplanned readmission was 3%, 7%, 11%, and 16% in patients treated with 0, 1, 2, or 3 preoperative medication classes (trend analysis p = 0.02). No significant differences were observed between patient groups treated with 0, 1, 2, or 3 preoperative immunosuppressive therapies with respect to patient, disease, or surgical factors.

CONCLUSIONS

Unplanned hospital readmission occurs frequently (8.3%) after surgery for Crohn's disease. Combination immunosuppressive therapy before surgery in patients with Crohn's disease appears to be associated with an increased incidence of postoperative unplanned hospital readmission.

摘要

背景

皮质类固醇、免疫调节剂和生物制剂经常联合使用,用于治疗克罗恩病。回顾性研究对于术前免疫抑制治疗对克罗恩病手术后并发症的影响得出了相互矛盾的结果。计划外住院再入院被认为是手术质量护理的指标。

目的

本研究旨在检查术前免疫抑制治疗次数与克罗恩病患者手术后计划外住院再入院之间的关联。

设计

从一个前瞻性维护的数据库中确定需要腹部手术的克罗恩病连续患者。手术前 3 个月内的术前免疫抑制治疗分为 3 类:皮质类固醇、免疫调节剂和生物制剂。

主要观察指标

评估出院后 30 天内发生的计划外再入院情况。采用 Cochrane-Armitage 检验进行趋势分析。

结果

研究组包括 338 例患者。术前医疗治疗包括皮质类固醇(n = 199;59%)、免疫调节剂(n = 162;48%)和生物制剂(n = 59;18%)。63 例(19%)患者术前未接受任何免疫抑制药物治疗,148 例(44%)、108 例(32%)和 19 例(6%)患者分别接受 1、2 或 3 类免疫抑制药物治疗。28 例(8.3%)患者发生计划外再入院。皮质类固醇治疗组(11%)、免疫调节剂治疗组(9%)和生物制剂治疗组(12%)的计划外再入院发生率相似。接受 0、1、2 或 3 种术前药物治疗的患者中,计划外再入院的发生率分别为 3%、7%、11%和 16%(趋势分析 p = 0.02)。在患者、疾病或手术因素方面,接受 0、1、2 或 3 种术前免疫抑制治疗的患者组之间没有观察到显著差异。

结论

克罗恩病手术后计划外住院再入院的发生率很高(8.3%)。术前联合免疫抑制治疗克罗恩病似乎与术后计划外住院再入院发生率增加有关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验